Update to the study protocol Face Your Fears: Virtual reality-based cognitive behavioral therapy (VR-CBT) versus standard CBT for paranoid ideations in patients with schizophrenia spectrum disorders: a randomized clinical trial.
Activities of daily living
Cognitive behavioral therapy
Delusions
Ideas of reference
Paranoid ideations
Schizophrenia spectrum disorders
Schizotypal disorders
Social functioning
Virtual reality
Virtual reality exposure therapy
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
23 Jan 2023
23 Jan 2023
Historique:
received:
05
12
2022
accepted:
03
01
2023
entrez:
23
1
2023
pubmed:
24
1
2023
medline:
26
1
2023
Statut:
epublish
Résumé
We unfortunately need to make an update to our published study protocol that describes a significant change in the design of the study. The Committee on Health Research Ethics of the Capital Region Denmark recently rejected the approval of changing the primary outcome in the trial, on the invariable grounds that the trial has already commenced. It is therefore necessary to retain the Green Paranoid Thought Scale (GPTS) part B, ideas of persecution, as our primary outcome, and GPTS part A, ideas of social reference, as a secondary outcome, which is described opposite in our published study protocol. The exchange of outcomes has not affected participation in our trial or the informed consent. Intervention in both groups and assessments are unchanged. The two outcomes together constitute GPTS and the unifying concept we attempt to treat, namely paranoid ideations. As this is a blinded, methodologically rigorous trial, we did not have-and still do not have-access to preliminary data, and therefore, we have no knowledge of the distribution of our two intervention groups nor the potential effect of the intervention. The power calculation remains unchanged irrespective of the selection of the primary outcome. We have been fully transparent with the changes in primary and secondary outcomes on ClinicalTrials.gov throughout the trial. Due to the considerations mentioned above, we assumed that there would not be any ethical implications of the change of primary outcome. We sincerely apologize for the irregularity caused because of this assumption.Trial registrationClinicalTrials.gov NCT04902066 . Initial release April 19th, 2021.
Identifiants
pubmed: 36691039
doi: 10.1186/s13063-023-07069-7
pii: 10.1186/s13063-023-07069-7
pmc: PMC9872344
doi:
Banques de données
ClinicalTrials.gov
['NCT04902066']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
52Subventions
Organisme : TrygFonden
ID : 148727
Organisme : Danmarks Frie Forskningsfond
ID : 0134-00066B
Organisme : Region Hovedstaden
ID : A6622
Informations de copyright
© 2023. The Author(s).
Références
Trials. 2022 Aug 15;23(1):658
pubmed: 35971137